About Us

Imagen Therapeutics was set up in 2007 by two industry experts to provide a chemosensitivity test that helps identify those agents that are most likely to be effective against a patient’s individual cancer. The test uses very specific High Content Screening assays that measure cell death, enabling the direct screening of patient’s cancers against a large number of possible chemotherapy treatments.

The company continues to grow in size with a very strong management team led by Dr Jonathan Engler (CEO) and Mr Steve Kent (Chairman).